Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Anjali Narayan Avadhani"'
Autor:
Italo Poggesi, Anjali Narayan Avadhani, Peter De Porre, Ruben Faelens, Lilian Y. Li, Daniele Ouellet, Quentin Leirens, Anne OHagan, Juan Jose Perez Ruixo, Elodie Valade, Anne-Gaëlle Dosne, Kim Stuyckens
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 11:569-580
A population pharmacokinetic (PK)-pharmacodynamic (PD) model was developed using data from 345 patients with cancer. The population PK-PD model evaluated the effect of erdafitinib total and free plasma concentrations on serum phosphate concentrations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b29331bc27042f9736568a48f4cbb86
https://doi.org/10.1002/psp4.12727
https://doi.org/10.1002/psp4.12727
Autor:
Michael J. Morris, A. Oliver Sartor, Jeffrey Y.C. Wong, Steven I Max, Hong Xie, Alex Yu, Chaitanya R. Divgi, Daniel Patricia, Anjali Narayan Avadhani, Neeta Pandit-Taskar, Pedro C. Barata, Luke T. Nordquist
Publikováno v:
Journal of Clinical Oncology. 40:TPS5104-TPS5104
TPS5104 Background: Radioligand therapy for metastatic castration resistant prostate cancer (mCRPC) has been shown to prolong survival, delay disease progression, and improve quality of life, raising hopes that these gains will be amplified with even
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d59c5186763fe8d09ca46b23ebebb65
https://doi.org/10.1200/jco.2022.40.16_suppl.tps5104
https://doi.org/10.1200/jco.2022.40.16_suppl.tps5104
Autor:
Michael J. Morris, A. Oliver Sartor, Jeffrey Y.C. Wong, Steven I Max, Hong Xie, Mike Russell, Chaitanya R Divgi, Daniel Patricia, Anjali Narayan Avadhani, Luke T. Nordquist
Publikováno v:
Journal of Clinical Oncology. 40:TPS206-TPS206
TPS206 Background: Radioligand therapy for metastatic castration resistant prostate cancer (mCRPC) has been shown to prolong survival, delay disease progression, and improve quality of life, raising hopes that these gains will be amplified with even
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59a85b26b7fd542090fb2dd45a4d79b8
https://doi.org/10.1200/jco.2022.40.6_suppl.tps206
https://doi.org/10.1200/jco.2022.40.6_suppl.tps206
Autor:
Manish Monga, Robert Huddart, Arlene O. Siefker-Radtke, Anjali Narayan Avadhani, P. De Porre, A. Santiago-Walker, Arash Rezazadeh, Yauheniya Cherkas, Earle F. Burgess, Anne OHagan, Christopher Moy, Andrea Necchi, Y. Loriot
Publikováno v:
Annals of Oncology. 31:S584
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96076a29b1348e091f7cd682c52ba1eb
https://doi.org/10.1016/j.annonc.2020.08.823
https://doi.org/10.1016/j.annonc.2020.08.823
Autor:
Neeta Pandit-Taskar, Mike R. Russell, Joseph A. O' Donoghue, Anjali Narayan Avadhani, Dushen Chetty, Michael J. Morris, Chaitanya R. Divgi, Emma Zulch
Publikováno v:
Journal of Clinical Oncology. 38:TPS249-TPS249
TPS249 Background: Human kallikrein-2 (hk2) is a member of the kallikrein family, is produced by prostatic epithelium, has 80% DNA sequence homology with PSA, is both circulating and bound to prostatic tissue, and is highly expressed even in high gra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f47ea7c53faaf3f8f51b06b7e4c8fb03
https://doi.org/10.1200/jco.2020.38.6_suppl.tps249
https://doi.org/10.1200/jco.2020.38.6_suppl.tps249
Autor:
Ian McCaffery, Peter De Porre, Christopher Moy, Anjali Narayan Avadhani, Matthew V. Lorenzi, Arlene O. Siefker-Radtke, Clifford Motley, Yohann Loriot, Yauheniya Cherkas, Ademi E. Santiago-Walker, Anne OHagan
Publikováno v:
Journal of Clinical Oncology. 37:420-420
420 Background: Plasma samples from a Phase 2 study of the pan-FGFR inhibitor erdafitinib in advanced UC patients (pts) with FGFR mutations (mut) or fusions, were tested using next generation sequencing (NGS) for circulating tumor DNA (ctDNA), and re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be92964bfd0615773e8f1d8ea44cac31
https://doi.org/10.1200/jco.2019.37.7_suppl.420
https://doi.org/10.1200/jco.2019.37.7_suppl.420
Autor:
Bob Zhong, Scott T. Tagawa, Begoña Mellado, Yohann Loriot, Se Hoon Park, Sergei Varlamov, Monika Joshi, Jesús GarcÃa-Donas, Arlene O. Siefker-Radtke, Mark D. Fleming, Arash Rezazadeh, Andrea Necchi, Anjali Narayan Avadhani, Anne OHagan, Robert Huddart, Earle F. Burgess, Peter De Porre, Ignacio Duran
Publikováno v:
Journal of Clinical Oncology. 36:4503-4503
4503Background: ERDA is an FGFR inhibitor with activity in pts with mUC and FGFRalt. FGFRalt occur in 10-20% of mUC and are enriched in immunologically “cold” luminal 1 UC. Two independent published reports showed a 5% investigator-reported respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f055200a7bfc5aa8e8ff1dc300496aa8
https://doi.org/10.1200/jco.2018.36.15_suppl.4503
https://doi.org/10.1200/jco.2018.36.15_suppl.4503
Autor:
Peter H. O'Donnell, Anjali Narayan Avadhani, Tito Roccia, Ademi E. Santiago-Walker, Scott T. Tagawa, Yohann Loriot, Earle F. Burgess, Eli Rosenbaum, Stéphane Culine, Anne OHagan, Arlene O. Siefker-Radtke, Bob Zhong, Yousef Zakharia, Andrea Necchi
Publikováno v:
Journal of Clinical Oncology. 36:450-450
450 Background: FGFR3 mutations appear to be enriched in luminal 1 UC, which have low expression of markers associated with an immune response, including CD8-T-effector gene expression levels. Objective response rate (ORR) to PD-1 and PD-L1 inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db95662c64016e760dbad86a7cba38bf
https://doi.org/10.1200/jco.2018.36.6_suppl.450
https://doi.org/10.1200/jco.2018.36.6_suppl.450
Autor:
Anjali Narayan Avadhani, Mark D. Fleming, Begoña Mellado, Arash Rezazadeh, Se Hoon Park, Yohann Loriot, Sergei Varlamov, Earle F. Burgess, Ignacio Duran, Robert Huddart, Anne-Gaëlle Dosne, Arlene O. Siefker-Radtke, Anne OHagan, Kim Stuyckens, Bob Zhong, Andrea Necchi, Jesús García-Donas, Monika Joshi
Publikováno v:
Journal of Clinical Oncology. 36:411-411
411 Background: Although immune checkpoint inhibitors (ICI) have improved outcomes in some pts with platinum-resistant mUC, many pts (eg, pts with TCGA luminal 1 tumors, many of whom are FGFRa) may not benefit. ERDA, a pan-FGFR (1-4) inhibitor, demon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3528030ec7d2784c2fe19d1ac679a5c5
https://doi.org/10.1200/jco.2018.36.6_suppl.411
https://doi.org/10.1200/jco.2018.36.6_suppl.411
Autor:
Sabine Brookman-May, Anjali Narayan Avadhani, Anne OHagan, A. Santiago-Walker, Karel Decaestecker, Arlene O. Siefker-Radtke, Begoña Mellado, John M. Burke, Bob Zhong, Jesús García-Donas, P. De Porre
Publikováno v:
Annals of Oncology. 27:vi293
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5d36ed618ee6f717169286d4c8d83af8
https://doi.org/10.1093/annonc/mdw373.72
https://doi.org/10.1093/annonc/mdw373.72